{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.9","upperLimit":"7.5","value":"6.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"461"}],"units":"Participants"}],"description":"Time to first subsequent therapy (TFST) was defined as the time from the date of first dose to the date of first subsequent therapy or death, whichever occurs first. It was calculated as (Earlier of \\[First dose of first subsequent therapy or death\\] minus First dose date plus 1) divided by 30.4375.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Niraparib (300 milligram \\[mg\\], taken as 3 capsules of 100 mg once daily \\[QD\\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.","id":"OG000","title":"Niraparib 300 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Time to First Subsequent Therapy (TFST)","type":"SECONDARY","unitOfMeasure":"Months"}